Beta- lactamase suppressing antibacterial compound drugs

Abstract

The invention discloses a beta- lactamase suppressing antibacterial compound drugs, which comprises ceftizoxime, or cefodizime and beta-lactam enzyme inhibitor by the active acid weight ratio of 1-10:10-1, which are in the forms of alkali metal salts or free acid and assisting solvents, the beta-lactam enzyme inhibitor can be Tazobactam, or clavulanic acid, or tapazole or their derivatives.

Description

technical field [0001] The present invention relates to a kind of antibiotic compound drug that inhibits the β-lactamase produced by bacteria, specifically a kind of β-lactamase inhibitor and the third generation cephalosporin antibiotic—Ceftizoxime (Ceftizoxime) or cefodizime ( Cefodizime) is a compound preparation composed of compatibility. Background technique [0002] Cephalosporin antibiotics have been widely used clinically, and have achieved therapeutic effects that are difficult to achieve with traditional antibiotics. However, due to the long-term and extensive clinical use of antibiotics, and even the abuse of antibiotics, bacteria have become increasingly resistant to antibiotics. For example, penicillin in β-lactams was particularly effective when used 200,000 units each time in clinical practice in the 1950s, but now it is difficult to achieve results when 800,000 units are used each time. Cephalosporins, which belong to the same β-lactam c...

AI Technical Summary

Problems solved by technology

[0005] The present invention aims at the problem that the curative effect of ceftizoxime and cefodizime is reduced due to drug-resistant bacteria producing β-lactamase, and provides an antibacterial combination drug for inhibiting β-lactamase

To protect ceftizoxime or cefodizime from being destroyed by β-lactamase produced by bacteria, and enhance its curative effect, so as to solve the problem of bacterial resistance to ceftizoxime or cefodizime